Logo of Recce Pharmaceuticals (ASX:RCE)Latest Recce Pharmaceuticals (ASX:RCE) News

Page 2
Page 2 of 5

Recce Pharmaceuticals Secures Vietnamese Patent for Novel Anti-Infectives Until 2041

Recce Pharmaceuticals has expanded its intellectual property footprint with a key patent granted in Vietnam for its RECCE® anti-infective drugs, reinforcing its presence in a critical Southeast Asian market grappling with high antibiotic resistance.
Victor Sage
14 July 2026

Healthcare Wrap - Week 27 (29 June -> 3 July) 2026

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.
Logan Eniac
4 July 2026

Recce Pharmaceuticals Boosts Cash with A$3.7 Million Tax Refund Ahead of Phase 3 Trials

Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.
Ada Torres
1 July 2026

Market Wrap - Week 26 (22 June -> 26 June) 2026

Big moves came from small and mid-cap names tied to drilling, project studies and fresh funding. Healthcare, mining and takeover stocks all had a busy week, but not every strong announcement held its gains.
Logan Eniac
27 June 2026

Healthcare Wrap - Week 26 (22 June -> 26 June) 2026

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.
Logan Eniac
27 June 2026

Recce Pharmaceuticals Raises A$4 Million to Fuel Licensing and Clinical Trials

Recce Pharmaceuticals secured A$4 million through an institutional placement and launched a Share Purchase Plan to raise up to an additional A$4 million, bolstering funds for commercial licensing and ongoing clinical programs.
Ada Torres
26 June 2026

Recce Pharmaceuticals Expands Phase 3 Trial for Diabetic Foot Infections with Broader Patient Scope

Recce Pharmaceuticals has secured ethics approval to upgrade and broaden its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, accelerating recruitment and reinforcing its global registration ambitions.
Ada Torres
22 June 2026

Market Wrap - Week 22 (25 May -> 29 May) 2026

Speculative small caps drove the week, with Tasman Resources, Solis Minerals and Lithium Energy leading the board after funding, drilling and asset sale updates. At the other end, ASX Ltd and Arafura Rare Earths fell hard as investors reacted to higher costs and fresh equity issuance.
Logan Eniac
30 May 2026

Healthcare Wrap - Week 22 (25 May -> 29 May) 2026

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.
Logan Eniac
30 May 2026

Recce Pharmaceuticals Secures 10-Year Licensing Deal for R327 Gel in MENA

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.
Ada Torres
27 May 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Recce Pharmaceuticals Secures $5.3M R&D Rebate, Advances U.S. Army Burn Wound Collaboration

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.
Ada Torres
30 Apr 2026